Legend Biotech Corp - ADR Forecast, price target & analysts
Legend Biotech Corp - ADR Target price 2025 - Analyst rating & recommendation
Legend Biotech Corp - ADR Classifications & Recommendation:
Legend Biotech Corp - ADR Price Target
| Target Price | $79.25 |
| Price | $36.72 |
| Potential |
115.83%
register free of charge
|
| Number of Estimates | 22 |
|
22 Analysts have issued a price target Legend Biotech Corp - ADR 2026 .
The average Legend Biotech Corp - ADR target price is $79.25.
This is
115.83%
register free of charge
$95.00
158.71%
register free of charge
$56.29
53.30%
register free of charge
|
|
| A rating was issued by 27 analysts: 25 Analysts recommend Legend Biotech Corp - ADR to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Legend Biotech Corp - ADR stock has an average upside potential 2026 of
115.83%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 285.14 | 619.92 |
| 143.69% | 117.41% | |
| EBITDA Margin | -147.92% | -43.84% |
| 60.63% | 70.36% | |
| Net Margin | -189.15% | -24.47% |
| 57.07% | 87.06% |
22 Analysts have issued a sales forecast Legend Biotech Corp - ADR 2024 . The average Legend Biotech Corp - ADR sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Legend Biotech Corp - ADR EBITDA forecast 2024. The average Legend Biotech Corp - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Legend Biotech Corp - ADR Analysts have issued a net profit forecast 2024. The average Legend Biotech Corp - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.94 | -0.83 |
| 4.63% | 71.77% | |
| P/E | negative | |
| EV/Sales | 9.47 |
11 Analysts have issued a Legend Biotech Corp - ADR forecast for earnings per share. The average Legend Biotech Corp - ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Legend Biotech Corp - ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Legend Biotech Corp - ADR...
Current Legend Biotech Corp - ADR Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 23 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 22 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 21 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Dec 30 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 10 2024 |
| Cantor Fitzgerald | Locked ➜ Locked | Locked | Dec 09 2024 |
| RBC Capital | Locked ➜ Locked | Locked | Dec 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 23 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 22 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 21 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Dec 30 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
Cantor Fitzgerald: Locked ➜ Locked
|
Dec 09 2024 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Dec 09 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
